Lycia Therapeutics prices upsized IPO at $317.5m on Nasdaq
Lycia Therapeutics has priced an upsized initial public offering of 17,640,000 shares at $18.00 per share, raising gross proceeds of approximately $317.5 million before underwriting costs and expenses. The South San Francisco company's stock is expected to begin trading on the Nasdaq Global Select Market on 23 October 2026 under the ticker "LYCA", with the offering scheduled to close on 26 October, subject to customary conditions.
The IPO was upsized from its originally filed size, suggesting healthy institutional demand. Underwriters also hold a 30-day greenshoe option to purchase up to an additional 2,646,000 shares at the offer price, which could add roughly $47.6 million in further proceeds if exercised in full. Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are acting as joint book-running managers, with LifeSci Capital as passive book-runner.
The platform and pipeline
Lycia's central technology is its LYTAC (Lysosomal Targeting Chimera) platform, which routes disease-causing extracellular and membrane proteins to the lysosome for degradation. The company says its next-generation cataLYTAC degraders are designed to work catalytically, meaning a single molecule can repeatedly eliminate target proteins rather than being consumed in a one-to-one reaction, a design principle intended to improve potency at lower doses.
Its two lead candidates illustrate the breadth of the autoimmune and allergic disease focus. LCA-0061 is a cataLYTAC degrader targeting immunoglobulin E (IgE) for food allergy and other allergic conditions, a programme that competes in a space where omalizumab (Xolair) is established but addresses only a subset of IgE-mediated disease. LCA-0321 is designed to selectively deplete the autoantibodies responsible for Graves' disease, a thyroid autoimmune condition with limited disease-modifying options. Lycia has not disclosed clinical-stage data for either candidate in this release, but both are described as clinical-stage assets.
The company was founded on the work of Carolyn Bertozzi, the Stanford University chemist and Howard Hughes Medical Institute investigator who was awarded the Nobel Prize in Chemistry in 2022 for her development of bioorthogonal chemistry. Bertozzi's laboratory was among the earliest to describe LYTAC technology in peer-reviewed literature, giving Lycia a distinctive academic foundation.
Market context
Targeted protein degradation has become one of the more competitive areas in drug discovery, with the field dominated to date by intracellular approaches: PROTACs and molecular glue degraders that engage the ubiquitin-proteasome system. Lycia's extracellular degradation strategy carves out a different niche, addressing proteins that PROTACs cannot reach because they are secreted or membrane-bound, including circulating antibodies, cytokines and receptor ligands.
A number of academic groups and well-funded start-ups are pursuing related lysosomal-targeting or receptor-mediated degradation strategies, meaning competitive pressure in the field is rising. However, Lycia's Nobel-laureate founding heritage and the size of this IPO suggest it enters the public markets with meaningful credibility and a capital base sufficient to advance both programmes through meaningful clinical readouts. Investors will look for early efficacy signals, particularly for LCA-0061 in food allergy, where biomarker-driven Phase 1 or 2 data could serve as a near-term catalyst.